scholarly article | Q13442814 |
P356 | DOI | 10.1002/HON.2346 |
P8608 | Fatcat ID | release_3zcb4mlr2revjmvn56pd2pjdtm |
P698 | PubMed publication ID | 27641429 |
P50 | author | Achilles Anagnostopoulos | Q42933010 |
Ioanna Sakellari | Q60227348 | ||
P2093 | author name string | Evangelia Yannaki | |
Eleni Gavriilaki | |||
Ioannis Batsis | |||
Despoina Mallouri | |||
Gerasimos Bamihas | |||
Kaloyannidis Kaloyannidis | |||
V Constantinou | |||
Zoi Boussiou | |||
P2860 | cites work | Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation | Q33366979 |
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation | Q33367451 | ||
Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis | Q33382787 | ||
Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning | Q33386036 | ||
Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. | Q33396969 | ||
Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis | Q33403897 | ||
Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults | Q33415603 | ||
A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab | Q33421822 | ||
Modified Ham test for atypical hemolytic uremic syndrome | Q33421884 | ||
The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy | Q33427838 | ||
Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination. | Q40722182 | ||
Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. | Q53091032 | ||
Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab | Q80155799 | ||
Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation | Q80252186 | ||
low body mass index is an independent risk factor for transplant-associated microangiopathy following total-body irradiation-based conditioning regimens | Q81817471 | ||
Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation | Q83931969 | ||
P433 | issue | 4 | |
P304 | page(s) | 932-934 | |
P577 | publication date | 2016-09-19 | |
P1433 | published in | Hematological Oncology | Q15762617 |
P1476 | title | Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases. | |
P478 | volume | 35 |
Q92600857 | Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions |
Q64094847 | Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics |
Q89987658 | Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy |
Q90499610 | Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease |
Q92798609 | Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal |
Q30235311 | Transplant-associated thrombotic microangiopathy: opening Pandora's box. |
Search more.